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Abstract
SNP in the vitamin D receptor (VDR) gene is associated with risk of lower respiratory infections. The influence of genetic variation in the
vitamin D pathway resulting in susceptibility to upper respiratory infections (URI) has not been investigated. We evaluated the influence of
thirty-three SNP in eleven vitamin D pathway genes (DBP, DHCR7, RXRA, CYP2R1, CYP27B1, CYP24A1, CYP3A4, CYP27A1, LRP2, CUBN and
VDR) resulting in URI risk in 725 adults in London, UK, using an additive model with adjustment for potential confounders and correction for
multiple comparisons. Significant associations in this cohort were investigated in a validation cohort of 737 children in Manchester, UK. In all,
three SNP in VDR (rs4334089, rs11568820 and rs7970314) and one SNP in CYP3A4 (rs2740574) were associated with risk of URI in the
discovery cohort after adjusting for potential confounders and correcting for multiple comparisons (adjusted incidence rate ratio per additional
minor allele ≥1·15, Pfor trend ≤0·030). This association was replicated for rs4334089 in the validation cohort (Pfor trend= 0·048) but not for
rs11568820, rs7970314 or rs2740574. Carriage of the minor allele of the rs4334089 SNP in VDR was associated with increased susceptibility to
URI in children and adult cohorts in the United Kingdom.
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Upper respiratory infections (URI) (i.e. those affecting the
respiratory tract above the level of the vocal cords) are most
commonly of viral aetiology, although bacteria may also be
responsible(1). URI commonly result in work absence and pri-
mary care consultations and impose a major economic burden
on society(2). They also cause a majority of acute exacerbations
of asthma and chronic obstructive pulmonary disease
(COPD)(3), which represent the main cause of morbidity and
mortality in people with these conditions. Moreover, they are
frequently inappropriately treated with antibiotics(4), a practice
which contributes to the emergence of antimicrobial resistance.
In the absence of effective vaccines against the viruses that most
commonly cause URI, identification of alternative preventive
strategies is a research priority.
A growing body of evidence suggests that vitamin D sup-
plementation may reduce the risk of URI in some clinical con-
texts. Vitamin D metabolites favourably modulate innate
immune responses to respiratory viruses in vitro(5–9) and
numerous observational studies have reported independent
inverse associations between circulating concentrations of
25-hydroxyvitamin D (25(OH)D, the major circulating vitamin
D metabolite) and URI risk(10). Meta-analyses of randomised
controlled trials (RCT) of vitamin D supplementation for the
prevention of acute respiratory infections and asthma
Abbreviations: 25(OH)D, 25-hydroxyvitamin D; aGMR, adjusted geometric mean ratios; aIRR, adjusted incidence rate ratio; CCL, C-C motif ligand; CXCL, C-X-C
motif ligand; RSV, respiratory syncytial virus; RV, rhinovirus; URI, upper respiratory infection; VDR, vitamin D receptor.
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exacerbations (which are commonly precipitated by URI) have
reported protective effects that are strongest in those with the
lowest circulating 25(OH)D concentrations at baseline(11–13).
However, scepticism regarding protective effects of vitamin D
against URI remains: this may in part reflect limitations inherent
in the design of cross-sectional and case–control studies, where
the possibility of reverse causality cannot be excluded(10).
Genetic studies represent an alternative approach to assessing
whether the vitamin D pathway plays a causal role in protection
against URI; a key strength is that associations seen cannot be
attributed to reverse causality. In terms of mechanism, SNP in
the gene encoding the vitamin D receptor (VDR) may modify
the protective efficacy of vitamin D-mediated host responses,
for example, by influencing the structure of the VDR with
consequences for transcription of vitamin D-regulated genes
influencing immune function(14). VDR polymorphisms have
previously been reported to associate with susceptibility to
acute lower respiratory infections (LRI) in diverse set-
tings(15–18); to date, however, the influence of SNP in VDR on
susceptibility to URI has not been investigated. Moreover, no
study has investigated whether polymorphisms in other genes
in the vitamin D pathway that encode proteins are responsible
for vitamin D metabolism, transport and signalling associated
with URI risk. We, therefore, conducted an investigation to test
the hypothesis that one or more of the thirty-three SNP in
eleven vitamin D pathway genes (Fig. 1) influence the risk of
URI and are associated with pathogen-stimulated concentra-
tions of cytokines and chemokines. The association between
genotype and risk of URI was investigated in a discovery
cohort of 725 adults, with validation of positive hits in a
cohort of 737 children. Where genetic associations were
replicated in both cohorts, ex vivo host responses to viral sti-




The discovery cohort comprised a total of 725 adults who
participated in one of the three RCT of vitamin D supple-
mentation to prevent acute respiratory infections conducted in
London, UK, whose methods are described elsewhere(19–21). All
studies were approved by East London and The City Research
Ethics Committee 1 (Refs. 09/H0703/67, 09/H0703/76 and 09/
H0703/112), and written informed consent was obtained from
all participants before enrolment. The validation cohort com-
prised 737 children who were enrolled in the Manchester
Asthma and Allergy Study (MAAS), a population-based birth
cohort study whose methods are described elsewhere(22).
Children were recruited prenatally, and were born between
20 April 1995 and 13 April 2000. The study was approved by the
Research Ethics Committee Greater Manchester East, NRES
Committee (Ref. no. 14/NW/1309) and parents gave written
informed consent for their children to participate.
Procedures
Clinical data collection. At enrolment, participants in the dis-
covery cohort completed questionnaires detailing lifestyle and
demographic factors relating to risk of URI including smoking
history, influenza vaccination history, socio-economic position,
age, sex and racial/ethnic origin. A baseline blood sample was
collected from all participants for DNA extraction and isolation of
serum for determination of 25(OH)D concentration. For a
representative sub-set of 185 participants, a sample of whole
blood was also incubated with a panel of Toll-like receptor (TLR)
ligands and respiratory viruses for 24 h, as described in the
forthcoming paragraphs. Participants were invited back 2 weeks
after their baseline visit to be randomised to receive intervention
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Fig. 1. The vitamin D pathway. DHCR7 (A) encodes the 7-dehydrocholesterol reductase enzyme, which catalyses the conversion of 7-dehydrocholesterol to
cholesterol; CYP2R1, CYP3A4, and CYP27A1 (B) encode 25-hydroxylating cytochrome P450 enzymes; the vitamin D binding protein gene (DBP (C)) encodes the
principal vitamin D transport protein; LRP2 and CUBN (D) encode the proteins megalin and cubilin, respectively, involved in renal re-absorption of 25-hydroxyvitamin D
(25(OH)D) via receptor-mediated endocytosis; CYP27B1 (E) encodes the cytochrome P450 enzyme which 1-α-hydroxylates 25(OH)D to form 1,25-dihydroxyvitamin D
(1,25(OH)2D); CYP24A1 (F) encodes the cytochrome P450 enzyme responsible for 24-hydroxylating vitamin D metabolites including 25(OH)D and 1,25(OH)2D; VDR
(G) encodes the vitamin D receptor, which is ligated by 1,25(OH)2D and forms a heterodimer with the gene product of RXRA (H) – the retinoid X receptor – to mediate
the biological actions of vitamin D. Gene symbols are shown in grey.
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or control regimens as summarised in online Supplementary
Table S1 over a 1-year period, during which they completed a
daily diary of URI symptoms. Symptom scores were used to
define incident URI, as previously described, and validated in a
subset of participants in the Vitamin D supplementation in pre-
vention of influenza (ViDiFlu) trial(21) using PCR detection of
eleven respiratory viruses obtained by nasopharyngeal swabs.
MAASparticipants attended follow-up visits at the ages of 1, 3, 5,
8 and 11 years. At each visit, a validated questionnaire was used to
collect information on incidence of URI diagnosed by a primary
care physician. We extracted all data from primary care medical
records, including URI, emergency department admissions and
hospitalisations and prescriptions of asthma medications and oral
corticosteroids(23). Self-reported episodes were validated against
primary care records. Blood samples were collected at age 11
years for peripheral bloodmononuclear cell (PBMC) isolation and
cryopreservation pending ex vivo stimulation(24).
SNP selection in the discovery cohort. A literature search of
the PubMed database was performed to identify SNP previously
shown to associate with serum 25(OH)D concentration and/or
risk of non-skeletal disease(25). A total of fifty-four such SNP in
eleven genes in the vitamin D pathway were identified; their
function is illustrated in Fig. 1. TagSNP were selected based on
linkage disequilibrium information from the HapMap database
(release #27: phases 1, 2 and 3 – merged genotypes and fre-
quencies); ‘Utah residents with Northern and Western European
ancestry from the Centre d'Etude du Polymorphisme Humain
(CEPH) collection (CEU)’ dataset, represented the discovery
cohort, of whom 83% of participants were of White European
ethnic/racial origin. Using Bioinformatics’ Haploview program
(version 3.3), selecting the ‘pairwise tagging only’ option, set-
ting the r2 threshold to >0·8 and accepting a minimum geno-
type completeness of 75% and a minor allele frequency
threshold of 0·04, tagging reduced the number of alleles to be
genotyped from fifty-four to thirty-seven SNP. Subsequent to
closure of the HapMap database, tagging was re-checked using
the 1000 genomes reference set under the same parameters,
which highlighted two additional pairwise associations in the
SNP panel. Thus, rs11568820 was chosen to capture rs7976091
(r2 1·0), and rs1544410 was chosen to capture rs731236 (r2 1·0),
reducing the panel to thirty-five SNP.
DNA extraction and genotyping. For the discovery cohort,
genotyping was conducted at the Genome Centre at QueenMary
University of London. DNA was extracted from whole blood
using a salting-out method previously described(26) on the Bio-
mek FX robot (BeckmanCoulter), quantified using theNanodrop
spectrophotometer (Thermo Scientific) and normalised to 5 ng/
µl. In all, 10 ngDNAwere used as template for 2 µl TaqMan assays
(Applied Biosystems) performed on the ABI 7900HT platform in
384-well format and analysed with Autocaller software. Typing
for two SNP failed (rs6127118, CYP24A1 and rs11574010, VDR),
reducing the panel for analysis to thirty-three SNP.
For the validation cohort, genomic DNA was extracted from
blood using the phenol–chloroform method and genotyped on
an Illumina 610 quad array (Illumina) and quality controlled as
described previously(27). Genotypes were subsequently pre-
phased (SHAPEIT version 2.5.1) and imputed (IMPUTE2 version
2.3.2) with the 1000 genomes haplotypes – phase 3 integrated
variant set reference genotypes. In all, one SNP was genotyped
(rs4334089) and three SNPwere imputed (rs11568820, rs7970314
and rs2740574); their info scores(28) were 0·99, 0·99 and 0·97,
respectively.
Whole blood assays. Stocks of rhinovirus (RV)-1B, RV-16 and
respiratory syncytial virus (RSV) were prepared as previously
described(9). Samples of whole blood from a sub-set of parti-
cipants in the discovery cohort were stimulated with the fol-
lowing TLR ligands and pathogens in sterile ninety-six-well
polystyrene microplates (Corning Incorporated): polyinosinic:
polycytidylic acid (poly I:C; InvivoGen; working stock con-
centration 1mg/ml), resiquimod (R848; InvivoGen; working
stock concentration 10 µg/ml), RV-1B (working stock titre
8·8× 107 tissue culture infective dose 50% (TCID50)/ml), RV-16
(working stock titre 9·8× 107 TCID50/ml) and RSV (working
stock titre 4× 106 plaque-forming units/ml). In all, 180 μl of
whole blood was incubated with 20 μl of a solution/suspension
of the working stock of stimulant or vehicle (PBS) in a humi-
dified incubator at 37°C and 5% CO2 for 24 h. Supernatants
were then aspirated and stored at −80°C pending analysis by
multiplex ELISA (Human Cytokine Magnetic 30-Plex Panel;
Invitrogen), following manufacturer’s instructions. Concentra-
tions of the following inflammatory mediators were determined:
IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8 (C-X-C motif ligand (CXCL)-
8), IL-10, IL-12, IL-13, IL-15, IL-17, IL-1RA, IL-2R, interferon
(IFN)-α, IFN-γ, TNF, C-C motif ligand (CCL)-2 (monocyte che-
moattractant protein-1), CCL3 (macrophage inflammatory pro-
tein (MIP)-1α), CCL4 (MIP-1β), CCL5 (RANTES), CCL11
(eotaxin-1), CXCL9 (monokine induced by IFN-γ; MIG), CXCL10
(inducible protein (IP)-10), epidermal growth factor (EGF),
fibroblast growth factor (FGF)-basic, hepatocyte growth factor
(HGF), vascular endothelial growth factor (VEGF), granulocyte
colony-stimulating factor (G-CSF) and granulocyte-macrophage
colony-stimulating factor (GM-CSF).
Peripheral blood mononuclear cell assays. Methods of the
PBMC assays performed in the validation cohort are described
in detail elsewhere(24). Briefly, cryopreserved PBMC were
thawed and distributed in ninety-six-well plates (2× 105 cells
per well) before stimulation with respiratory viruses (RV1B,
RV16 and RSV, all at a multiplicity of infection (ratio of infec-
tious agents to infection targets) of 1), resiquimod (1 µM final
concentration) or medium. Supernatants were harvested 24 h
after stimulation and concentrations of IFN-α, IFN-γ, CXCL10,
IL-1β, IL-6 and TNF were measured with the Meso Scale Dis-
covery Multi-array.
Measurement of vitamin D status. Serum concentrations of
25(OH)D2 and 25(OH)D3 were determined by isotope-dilution
liquid chromatography–tandem MS in the Department of Clin-
ical Biochemistry at Homerton Hospital, and summed to give
total serum 25(OH)D concentration. The limit of detection for
25(OH)D2 and 25(OH)D3 was 10 nmol/l; mean percentage bias
VDR genotype and upper respiratory infection 3
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S000711451800209X
Downloaded from https://www.cambridge.org/core. Queen Mary, University of London, on 10 Sep 2018 at 12:58:44, subject to the Cambridge Core terms of use, available at
was −0·70 (SD 7·35); 95% limits of agreement were from −15·1 to
13·7. Undetectable results were treated as zero values. This
laboratory participates in the international vitamin D external
quality assurance scheme (www.deqas.org/).
Statistical analyses. Statistical analyses were conducted using
STATA version 12 and SNPTEST version 2.5.1. The influence of
genotype on rate of URI or proportion with one or more URI
was analysed with negative binomial regression and the
Cochran–Armitage test, respectively. All SNP were analysed
using the per-allele method, that is, under an additive model.
Regression models for the discovery cohort were adjusted for
the following potential confounders of the relationship between
genotype and URI risk: age, sex, racial/ethnic origin, influenza
vaccination history, smoking history, baseline vitamin D status,
allocation to vitamin D v. placebo and presence of respiratory
morbidity (asthma v. COPD v. none). Covariates were classified
as categorical variables, with the exception of age and baseline
vitamin D status, which were fitted as continuous variables. In
the validation cohort, participants whose parents identified their
ethnic origin as being other than ‘White European’ (3% of the
study population) were excluded from genetic analyses. Eth-
nicity was controlled for in the statistical analysis of the dis-
covery cohort and a sensitivity analysis excluding data from
participants who identified their ethnic origin as being other
than ‘White European’ (15% of the study population) was
performed for significant SNP–URI risk associations. An addi-
tional sensitivity analysis removing participants in the inter-
vention arm was performed on significant SNP–URI risk
associations in the discovery cohort to account for variation in
serum response to vitamin D supplementation. Supernatant
concentrations of inflammatory mediators were transformed to
their natural logarithms before regression analysis. Regression
coefficients were then exponentiated to give adjusted geometric
mean ratios (aGMR) with associated 95% CI and P values for
trend. The Benjamini–Hochberg procedure for multiple testing
correction was applied to analyse URI rate and immunological
data to control the false discovery rate (FDR) at 10%.
Results
Study populations
Characteristics of the 725 participants in the discovery cohort
are presented in Table 1. They ranged from 16 to 94 years of
age, with a mean of 59·7 (SD 15·0) years, and 54% were female.
In all, 67% of participants had respiratory comorbidity (34%
asthma; 33% COPD). The majority of participants classified
their racial/ethnic origin as ‘White European’ (85%); 9% clas-
sified their racial/ethnic origin as Black/Black British; 4% as
Asian/Asian British and 2% as mixed. At baseline, the mean
serum 25(OH)D concentration was 46·3 (SD 24·7) nmol/l.
Average duration of participation was 0·93 years, and partici-
pants had a total of 677 participant-years of follow-up. Immu-
nological data were available for 180 participants in the
discovery cohort; characteristics of this sub-set of participants
were similar to those of participants who did not contribute
immunological data (online Supplementary Table S2). Detailed
characteristics of the replication population are presented
elsewhere(24) and summarised in online Supplementary
Table S3. Briefly, 737 participants had data on URI and geno-
typing data. Average duration of participation was 9·97 years,
and participants had a total of 7350 participant-years of
follow-up. PBMC stimulation data and genotyping data were
available for 228 children.
Table 1. Baseline participant characteristics, discovery cohort
(Numbers and percentages; mean values and standard deviations)













Asian/Asian British 31 4·3













Quarter of blood draw
Q1 (January–March) 229 31·6
Q2 (April–June) 180 24·8
Q3 (July–September) 138 19·0












Chronic obstructive pulmonary disease 239 33·0
None 238 32·8









* Ethnicity not reported in n 3. Other ethnicities: n 7 White and Black Caribbean, n 2
White and Asian, n 2 White and Black African, n 1 Irish – Sri Lankan, n 1 Spanish –
Filipino, n 1 Asian Caribbean, n 1 Mauritian, n 2 preferred not to disclose.
† Socio-economic position not reported in n 9.
‡ Alcohol consumption not reported in n 13. One alcohol unit=8 g pure alcohol.
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Genetic determinants of upper respiratory infections risk
Results of statistical analyses to determine the influence of geno-
type on risk of URI in the discovery cohort are presented in
Table 2. After adjusting for potential confounders and correcting
for multiple comparisons testing, carriage of minor alleles for three
SNP in VDR and one SNP in CYP3A4 were found to associate with
increased URI risk. Adjusted incidence rate ratios (aIRR) per
additional minor allele, generated by additive models, are as fol-
lows: for rs4334089 in VDR, aIRR= 1·15, 95% CI 1·01, 1·31,
P=0·03; for rs11568820 in VDR, aIRR=1·23, 95% CI 1·07, 1·40,
P=0·002; for rs7970314, aIRR= 1·17, 95% CI 1·02, 1·34, P= 0·018;
and for rs2740574 in CYP3A4, aIRR=1·27, 95% CI 1·03, 1·56,
P=0·025. Results of two sensitivity analyses to determine the
influence of rs4334089, rs11568820, rs7970314 and rs2740574 on
risk of URI, restricted to participants of white European ethnicity
and the placebo arm, are presented in online Supplementary
Tables S4 and S5, respectively. All SNP–URI associations remained
significant (P≤ 0·048) for both sensitivity analyses. We also per-
formed an exploratory interaction analysis to determine whether
the influence of rs4334089 genotype on risk of URI in discovery
cohort participants was modified by baseline vitamin D status (25
(OH)D <25 v. ≥25nmol/l). We found no evidence of effect
modification (P value for interaction=0·38).
We then proceeded to investigate whether these SNP also
associated with susceptibility to URI in the validation cohort of
children. Results of these analyses are presented in Table 3. The
association between carriage of the minor allele for rs4334089
and increased susceptibility to URI originally observed in the
discovery cohort was replicated in the validation cohort: the
proportion of children experiencing at least one physician-
diagnosed URI with AA v. AG v. GG genotypes was 6/56
(10·7%) v. 23/278 (8·3%) v. 21/403 (5·2%), respectively
(Pfor trend= 0·048). No associations between imputed genotypes
for rs11568820, rs7970314 or rs2740574 and URI susceptibility
were seen in the validation cohort.
Genetic variation in ex vivo virus-stimulated inflammatory
profiles
Having replicated the association between rs4334089 genotype
and susceptibility to URI in separate cohorts of children and
adults, we proceeded to investigate whether genetic variation at
this locus was also associated with differences in host response
to ex vivo viral stimuli in both discovery and validation cohorts.
In the discovery cohort, concentrations of thirty inflammatory
mediators in supernatants of virus-stimulated whole blood were
compared between three groups of participants defined by their
rs4334089 genotype (GG v. AG v. AA). After correction for
potential confounders, statistically significant differences in
supernatant concentrations of four inflammatory mediators
were found (Fig. 2). Carriage of the minor allele of rs4334089 –
previously shown to associate with increased susceptibility to
URI – associated with lower supernatant concentrations of
IL-2R (RSV stimulation: aGMR 0·92, 95% CI 0·84, 0·99,
Pfor trend=0·047; poly I:C stimulation: aGMR 0·89; 95% CI 0·79,
0·99; P= 0·041), CCL5 (RV1-B stimulation: aGMR 0·66, 95% CI
0·46, 0·94, Pfor trend= 0·023), CXCL9 (RV-16 stimulation: aGMR
0·84, 95% CI 0·71, 1·00; Pfor trend= 0·054) and IL-1RA (RSV sti-
mulation: aGMR 0·91, 95% CI 0·83, 0·99; Pfor trend= 0·042).
rs4334089 genotype also influenced host response in the MAAS
validation cohort of children, where carriage of the minor allele
was associated with lower supernatant concentration of
resiquimod-stimulated CXCL10 (GMR 0·78, 95% CI 0·64, 0·96;
Pfor trend= 0·017; Fig. 2). However, none of these differences
remained statistically significant after correction for multiple
comparisons testing, using the Benjamini and Hochberg
method with a FDR of 10%.
Discussion
To our knowledge, this is the first study to investigate the
influence of genetic variation in the vitamin D pathway on URI
risk. We report that carriage of minor alleles for three SNP in
VDR (rs4334089, rs11568820 and rs7970314) and one SNP in
CYP3A4 (rs2740574) associated with increased risk of URI in a
cohort of adults after correction for potential confounders and
multiple comparison testing; these associations were robust to
sensitivity analysis restricted to those who classified their ethnic
origin as being ‘White European’. We achieved partial replica-
tion of these findings by additionally demonstrating an asso-
ciation between carriage of the minor allele for rs4334089 and
increased susceptibility to URI in a validation cohort of children.
Since the function of VDR is specific to vitamin D signalling, our
results complement the growing body of evidence from in vitro
studies, observational epidemiology and RCT suggesting that
vitamin D plays a role in defence against viral respiratory
infections.
Our study adds to the body of literature reporting associa-
tions between VDR polymorphisms and susceptibility to diverse
infectious diseases, including LRI(15–18,29). The mechanisms
underlying such associations have only been elucidated in
some cases: for example, the mutant allele of the FokI poly-
morphism encodes a shorter VDR protein that results in higher
NF-κB-driven transcription, enhanced expression of IL-12 and
more vigorous lymphocyte proliferation in response to phyto-
haemagglutinin(14). In the absence of evidence that the
rs4334089 polymorphism has similar functional consequences,
we presume that the association demonstrated here arises as a
result of this SNP being in linkage disequilibrium with a func-
tional variant elsewhere in the VDR gene that has yet to be
identified. Other studies have reported associations between
the rs4334089 genotype and susceptibility to Parkinson’s and
Alzheimer’s diseases(30), as well as responsiveness to vitamin D
supplementation in patients with tuberculosis(31).
Our immunological findings also have biological plausibility:
since vitamin D modulates TLR expression via VDR signal-
ling(32–34), it follows that genetic variation at the VDR has
potential to influence TLR ligand-stimulated responses. With
regard to specific cytokines and chemokines, IL-1RA plays a
key role in resolution of RV infection(35,36), while CCL5 has been
reported to inhibit RSV infection in a human respiratory epi-
thelial cell line(37) and to promote RSV clearance in mice(38).
CCL5, CXCL9 and CXCL10 recruit T lymphocytes in the context
of respiratory virus infection(37–40). Reduced production of these
VDR genotype and upper respiratory infection 5
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Table 2. Genetic determinants of upper respiratory infection risk, discovery cohort
(Numbers and 95% confidence intervals)
Gene SNP Genotype n
No. of URI per
person-year of follow-up Rate
Adjusted incidence
rate ratio per additional
minor allele* 95% CI Pfor trend
CUBN rs3740165 TT 651 1033/604·3 1·71 0·85 0·61, 1·18 0·34
TC 54 77/50·1 1·54
CC 2† 0/2·1 0·0
CYP24A1 rs2762939 GG 372 590/345·6 1·71 1·01 0·88, 1·17 0·85
CG 279 462/262·2 1·76
CC 60 82/52·1 1·57
rs2248137 CC 245 377/233·5 1·61 1·02 0·89, 1·15 0·82
CG 335 569/306·0 1·86
GG 133 181/122·0 1·48
rs2762934 GG 498 792/461·7 1·72 0·97 0·82, 1·14 0·70
AG 191 307/179·0 1·72
AA 22 22/18·3 1·20
rs6013897 TT 445 707/415·7 1·70 1·05 0·90, 1·21 0·55
AT 228 342/207·4 1·65
AA 37 71/34·0 2·09
CYP27A1 rs17470271 AA 279 416/261·9 1·59 1·08 0·95, 1·22 0·25
AT 323 551/293·8 1·88
TT 115 180/109·2 1·65
CYP27B1 rs4646537 TT 645 1019/599·8 1·70 1·02 0·74, 1·39 0·91
GT 63 97/56·6 1·71
GG 0† 0/0 0·0
rs4646536 AA 324 518/303·8 1·71 0·97 0·85, 1·10 0·61
AG 303 492/276·4 1·78
GG 81 114/75·7 1·51
CYP2R1 rs10500804 TT 269 405/248·7 1·63 1·08 0·95, 1·22 0·26
GT 340 561/313·9 1·79
GG 110 176/103·8 1·70
rs2060793 GG 249 427/233·1 1·83 0·92 0·81, 1·04 0·18
AG 340 523/311·0 1·68
AA 120 180/112·4 1·60
rs10766197 GG 233 352/217·0 1·62 1·07 0·94, 1·22 0·32
AG 342 561/313·6 1·79
AA 118 187/110·7 1·69
CYP3A4 rs2740574 AA 608 940/567·7 1·66 1·27 1·03, 1·56 0·025‡
AG 77 143/69·5 2·06
GG 33 60/29·4 2·04
DBP rs7041 CC 192 294/179·3 1·64 1·13 1·00, 1·29 0·060
AC 343 535/319·4 1·68
AA 173 287/157·6 1·82
rs4588 GG 382 587/356·5 1·65 1·11 0·96, 1·29 0·16
GT 290 483/269·3 1·79
TT 48 70/42·1 1·66
rs12512631 TT 305 459/284·0 1·62 1·00 0·88, 1·14 0·97
CT 331 526/303·1 1·74
CC 80 114/78·2 1·46
rs2070741 TT 603 944/561·1 1·68 0·93 0·73, 1·19 0·56
TG 102 171/93·4 1·83
GG 0† 0/0 0·0
rs2298849 AA 445 727/420·1 1·73 0·99 0·86, 1·15 0·93
AG 231 350/205·9 1·70
GG 40 66/38·1 1·73
rs16846876 AA 340 546/317·7 1·72 1·00 0·86, 1·16 0·98
AT 323 520/297·7 1·75
TT 52 63/47·0 1·34
DHCR7 rs3829251 GG 532 827/492·1 1·68 1·04 0·87, 1·24 0·66
AG 162 273/151·8 1·80
AA 16 21/14·0 1·50
rs12785878 TT 394 618/364·1 1·70 1·10 0·95, 1·27 0·22
GT 241 372/227·2 1·64
GG 83 153/75·3 2·03
LRP2 rs3755166 GG 263 431/242·0 1·78 0·90 0·80, 1·03 0·12
AG 346 559/322·8 1·73
AA 112 156/103·7 1·50
RXRA rs7861779 GG 464 763/431·5 1·77 0·95 0·81, 1·12 0·60
GA 190 265/176·9 1·50
AA 44 81/38·6 2·10
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mediators in response to viral stimuli might, therefore, be
expected to increased susceptibility to URI. However, the fact
that genotypic differences in host response to viral stimuli did
not remain statistically significant after correction for multiple
comparisons testing indicates that these may have arisen due to
type 1 error, and our immunological findings should not,
therefore, be given undue weight.
Our study has several strengths. To our knowledge, it
represents the most comprehensive investigation into the
influence of genetic variation in the vitamin D pathway on
susceptibility to any infectious disease that has been conducted
to date, in terms of the number of vitamin D pathway genes
investigated. Any attendant potential for type 1 error in genetic
analyses was minimised by stringent adjustment for multiple
comparisons. We handled the potential for confounding by
adjusting for potential confounders, and by conducting appro-
priate sensitivity analyses. We utilised a PCR-validated defini-
tion of URI, and captured events prospectively using a detailed
symptom diary over a 1-year period. Our study population
incorporated a broad range of participants, with a wide range
of circulating 25(OH)D concentrations, with and without
respiratory comorbidity, which enhances generalisability of our
findings. The fact that we were able to replicate the association
between rs4334089 genotype and susceptibility to URI in
Table 2. Continued
Gene SNP Genotype n
No. of URI per
person-year of follow-up Rate
Adjusted incidence
rate ratio per additional
minor allele* 95% CI Pfor trend
rs9409929 GG 327 524/298·1 1·76 1·01 0·89, 1·16 0·85
AG 319 502/300·7 1·67
AA 69 117/63·7 1·84
VDR rs4334089 GG 361 528/334·4 1·58 1·15 1·01, 1·31 0·030‡
AG 266 455/246·1 1·85
AA 88 152/84·0 1·81
rs10783219 AA 320 536/297·8 1·80 0·93 0·82, 1·06 0·26
AT 298 447/277·1 1·61
TT 89 134/81·8 1·64
rs4516035 TT 285 458/263·5 1·74 0·91 0·80, 1·04 0·19
CT 316 510/294·3 1·73
CC 104 143/95·2 1·50
rs11568820 GG 409 589/376·7 1·56 1·23 1·07, 1·40 0·002‡
GA 217 373/204·1 1·83
AA 83 163/76·0 2·14
rs2238136 CC 409 689/382·0 1·80 0·93 0·81, 1·0 0·32
CT 258 367/237·1 1·55
TT 48 82/45·0 1·82
rs1544410 CC 254 361/230·5 1·57 1·10 0·97, 1·24 0·15
CT 340 548/317·3 1·73
TT 114 206/108·3 1·90
rs2228570 GG 302 459/282·1 1·63 1·07 0·94, 1·21 0·34
AG 318 517/295·3 1·75
AA 96 152/87·0 1·75
rs2853559 GG 280 455/262·6 1·73 0·94 0·82, 1·07 0·34
AG 334 524/306·3 1·71
AA 102 153/94·9 1·61
rs7975232 AA 211 344/198·3 1·73 0·95 0·84, 1·08 0·43
AC 349 566/323·2 1·75
CC 141 194/128·4 1·51
rs7970314 AA 394 584/361·7 1·61 1·17 1·02, 1·34 0·018‡
AG 230 390/218·0 1·79
GG 96 174/87·9 1·98
URI, upper respiratory infection; CUBN, cubilin; CYP-, cytochrome P450 enzyme; DBP, vitamin D binding protein; DHCR7, 7-dehydrocholesterol reductase enzyme; LRP2, low
density lipoprotein-related protein 2 (also known as megalin); RXRA, retinoid-X receptor-A; VDR, vitamin D receptor; COPD, chronic obstructive pulmonary disease.
* Adjusted for age, sex, ethnicity, smoking history, influenza vaccination history, allocation to vitamin D v. placebo, respiratory comorbidity (asthma v. COPD v. none).
† URI rate could not be calculated due to zero participants with the genotype or zero URI events.
‡ Significant after correction for multiple comparisons testing, using the Benjamini and Hochberg method with a false discovery rate of 10%.




with ≥1 URI % Pfor trend
CYP3A4 rs2740574 AA 48/691 6·9 0·63
AG 2/45 4·4
GG 0/1 0·0
VDR rs4334089 GG 21/403 5·2 0·048
AG 23/278 8·3
AA 6/56 10·7
rs11568820 GG 27/458 5·9 0·19
GA 19/238 8·0
AA 4/41 9·8
rs7970314 AA 26/437 5·9 0·26
AG 20/256 7·8
GG 4/44 9·1
URI, upper respiratory infection; CYP-, cytochrome p450 enzyme; VDR, vitamin D
receptor.
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diverse clinical cohorts (children v. adults), using a different
case definition for URI (physician-diagnosed URI v. diary-
defined URI), adds weight to this finding.
Our study also has some limitations. Our results are asso-
ciative and descriptive; until a mechanism by which this VDR
polymorphism influences susceptibility to URI is demonstrated,
causal inferences should not be drawn. Our immunological
studies investigated host responses in peripheral blood only;
these may not reflect responses in the airway. Moreover,
immunological data were only available for a sub-set of parti-
cipants, and consequently the numbers of minor homozygotes
contributing to analyses of inflammatory mediator concentra-
tions were small: power to detect small differences in host
response by genotype was, therefore, limited. It could be
argued that our discovery and validation cohorts were too dif-
ferent in terms of age range to represent a true replication.
However, the virology of URI in schoolchildren and adults in
the UK is broadly comparable, in that RV are responsible for the
majority of events in both populations(41,42). Moreover,
vitamin D supports broad-spectrum innate antiviral responses,
which are effective against different respiratory viruses(7). Our
finding that genetic variation in VDR associates with suscept-
ibility to URI in both children and adults is also consistent with
findings from our recent individual participant data meta-
analysis of randomised trials, which showed an overall pro-
tective effect of vitamin D supplementation against URI in
participants aged 0–95 years, with strongest effects seen in
those with the lowest 25(OH)D levels receiving daily or weekly
vitamin D supplementation(12). In the validation cohort, it is
likely that only a sub-set of URI were captured, since only
relatively severe episodes of URI are likely to present to primary
care. However, the fact that captured episodes were physician-
diagnosed provides extra confidence that diagnoses were
accurate. Our study was also limited by the fact that we did not
characterise viruses responsible for URI episodes; accordingly,
we were unable to investigate whether VDR genotype influences
susceptibility to URI in a pathogen-specific manner. Further
research incorporating virological diagnosis could provide insight
into this question; such studies may be challenging, as sensitivity
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Fig. 2. Concentrations of virus-stimulated immune mediators by rs4334089 genotype. (a) Rhinovirus (RV)-16-stimulated C-X-C motif ligand (CXCL)-9, whole blood
supernatant (discovery cohort, n 101); (b) RV-1B-stimulated C-C motif ligand (CCL)-5, whole blood supernatant (discovery cohort, n 56); (c) respiratory syncytial virus
(RSV)-stimulated IL-1RA, whole blood supernatant (discovery cohort, n 101); (d) RSV-stimulated IL-2R, whole blood supernatant (discovery cohort, n 101); (e)
polyinosinic:polycytidylic acid (poly I:C)-stimulated IL-2R, whole blood supernatant (discovery cohort, n 180); (f) resiquimod-stimulated CXCL10, peripheral blood
mononuclear cell supernatant (validation cohort, n 228). P values are from regression analysis of log-transformed data; none was significant after correction for
multiple comparisons testing, using the Benjamini and Hochberg method with a false discovery rate of 10%.
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sampling is delayed after onset of symptoms(43). Finally, we draw
attention to the fact that the vitamin D status of participants in our
discovery cohort was relatively low (20% <25nmol/l, 61%
<50nmol/l): if the genetic associations reported are modified by
circulating concentrations of 25(OH)D, they may not be repli-
cated in populations with higher vitamin D status.
In conclusion, we report that a polymorphism in VDR inde-
pendently associates with susceptibility to URI in both adults
and children. Given that the VDR is exclusively involved in
vitamin D signalling, our findings lend weight to the growing
body of evidence suggesting a role for the vitamin D pathway in
mediating protection against respiratory infections.
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